SCHEMBL2679277

SCHEMBL2679277

Cc1cn(-c2cc(NC(=O)c3ccc(C)c(NC(=O)C=Cc4cncnc4)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB2 P29323 2/20 0.65
ABL1 P00519 9/20 0.63
SRC P12931 2/20 0.63
HCK P08631 2/20 0.61
NR2C2 P49116 1/20 0.61
BTK Q06187 1/20 0.61
DDR1 Q08345 5/20 0.60
BCR P11274 5/20 0.60
DDR2 Q16832 4/20 0.60
NTRK3 Q16288 3/20 0.60
NTRK2 Q16620 2/20 0.60
NTRK1 P04629 1/20 0.60
ADORA3 P0DMS8 2/20 0.59
NR1I2 O75469 1/20 0.59
PTGS1 P23219 1/20 0.59
KDR P35968 1/20 0.59
CHRNA4 P43681 1/20 0.59
PDE3A Q14432 1/20 0.59
KIT P10721 3/20 0.59
PDGFRB P09619 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078661 1.00 EPHB2 (0.65) EPHB2ABL1SRCHCKNR2C2
SCHEMBL2679133 0.92 ABL1 (0.69) EPHB2ABL1SRCHCKNR2C2
SCHEMBL2679307 0.87 KIT (0.62) EPHB2ABL1SRCHCKNR2C2
SCHEMBL2679904 0.85 BRAF (0.49) EPHB2ABL1SRCHCKNR2C2
SCHEMBL10077762 0.85 BRAF (0.49) EPHB2ABL1SRCHCKNR2C2
SCHEMBL28382296 0.83 EPHB2 (0.77) EPHB2ABL1SRCHCKNR2C2
SCHEMBL30546751 0.83 EPHB2 (0.77) EPHB2ABL1SRCHCKNR2C2
SCHEMBL22065195 0.83 EPHB2 (0.75) EPHB2ABL1SRCHCKNR2C2
SCHEMBL16867179 0.82 EPHB2 (0.74) EPHB2ABL1SRCHCKNR2C2
SCHEMBL30546654 0.82 EPHB2 (0.74) EPHB2ABL1SRCHCKNR2C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US claimed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US claimed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR EPHB2 2694/4885ABL1 1/4885SRC 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.